Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma (Q36119828)

12 August 2017

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma (English)

1 reference

12 August 2017

0 references

1 reference

1 reference

7

N P Restifo

1 reference

12 August 2017

S A Rosenberg

1

1 reference

12 August 2017

J C Yang

2

1 reference

12 August 2017

D J Schwartzentruber

3

1 reference

12 August 2017

P Hwu

4

1 reference

12 August 2017

F M Marincola

5

1 reference

12 August 2017

S L Topalian

6

1 reference

12 August 2017

M E Dudley

8

1 reference

12 August 2017

S L Schwarz

9

1 reference

12 August 2017

P J Spiess

10

1 reference

12 August 2017

J R Wunderlich

11

1 reference

12 August 2017

M R Parkhurst

12

1 reference

12 August 2017

Y Kawakami

13

1 reference

12 August 2017

C A Seipp

14

1 reference

12 August 2017

J H Einhorn

15

1 reference

12 August 2017

D E White

16

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 March 1998

1 reference

12 August 2017

1 reference

12 August 2017

4

1 reference

12 August 2017

3

1 reference

12 August 2017

321-327

1 reference

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Insertion signal sequence fused to minimal peptides elicits specific CD8 T-cell responses and prolongs survival of thymoma-bearing mice.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Limiting dilution analysis of human T cells: a useful clinical tool

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

The development of new cancer therapies based on the molecular identification of cancer regression antigens

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8 CTL in vivo with peptide vaccine constructs.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

Herpes simplex virus class I-restricted peptide induces cytotoxic T lymphocytes in vivo independent of CD4 T cells.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2064864

CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

23 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038/NM0398-321

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3

21 January 2018

1 reference

12 December 2020

Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine

1 reference

12 December 2020

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo

1 reference

12 December 2020

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues

1 reference

12 December 2020

Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides

1 reference

12 December 2020

Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells

1 reference

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

12 December 2020

Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct

1 reference

12 December 2020

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

12 December 2020

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

12 December 2020

Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells

1 reference

12 December 2020

Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients

1 reference

12 December 2020

Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression

1 reference

12 December 2020

Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides

1 reference

12 December 2020

Differential Anti-MART-1/MelanA CTL Activity in Peripheral Blood of HLA-A2 Melanoma Patients in Comparison to Healthy Donors

1 reference

Crossref

https://api.crossref.org/works/10.1038/NM0398-321

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NM0398-321

1 reference

Dimensions Publication ID

12 August 2017

0 references

1 reference

12 August 2017

PubMed publication ID

9500606

1 reference